Case Report
Lumbar Ureteral Stenosis due to Endometriosis: Our Experience and Review of the Literature
Table 1
Tumour markers and hormonal levels.
| Analyte | Value | Normal range |
| Tumour markers values |
| CA 125 (cancer antigen 125) | 21,84 UI/mL | 0–33 UI/mL | CA 19.9 (cancer antigen 19.9) | 8,25 UI/mL | 0–40 UI/mL | CEA (carcinoembryonic antigen) | 0,46 ug/mL | Nonsmoker (as was the patient): 0–3 ug/mL. | AFP (alpha-fetoprotein) | 0,97 ng/mL | 0–7,5 ng/mL |
| Hormonal levels |
| FSH (follicle stimulating hormone) | 4.46 mIU/mL | Follicular phase (as was the patient): 3,5–12,5 mIU/mL | LH (luteinizing hormone) | 3.04 mIU/mL | Follicular phase (as was the patient): 2,4–12,6 mIU/mL | E2 (17 β estradiol) | 227 pg/mL | Follicular phase (as was the patient): 12,5–166 pg/mL | PG (progesterone) | 0,70 ng/mL | Follicular phase (as was the patient): 0,2–1,5 ng/mL | β-HCG (β-human chorionic gonadotropin) | Negative | |
|
|